{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:19:09Z","timestamp":1768090749306,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Inflamm"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The goal of the present study was to explore the effect of medications that are commonly prescribed for CKD patients on uremic state.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This was a cross-sectional study. From January 2006 to October 2009, 1,623 patients with end-stage kidney disease (ESKD) commenced hemodialysis (HD) at the 9 participating hospitals. The criteria for exclusion from the database were 1) serum C-reactive protein (CRP)\u2009&gt;\u20093\u2009mg\/dL, 2) WBC count\u2009&gt;\u20099,000\/mm<jats:sup>3<\/jats:sup> or &lt;4,000\/mm<jats:sup>3<\/jats:sup>, and 3) patients with cancer, immune complex disease, or vasculitis. A total of 900 patients were entered into the final database. We explored the association of serum CRP just before the first HD session with clinical characteristics, laboratory data, and medications for CKD in the predialysis period.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>On univariate analysis, age, CTR, eGFR, and WBC were significantly correlated with CRP. Systolic and diastolic blood pressure, serum albumin, LDL-C, HDL-C, Hb, Cr, and Ca were inversely associated with CRP. Use of erythropoietin-stimulating agents (ESA) using (r\u2009=\u2009\u22120.111, p\u2009=\u20090.0015), renin-angiotensin-aldosterone system inhibitors (r\u2009=\u2009\u22120.083, p\u2009=\u20090.0154), and calcium channel blockers (r\u2009=\u2009\u22120.1, p\u2009=\u20090.0039) was also negatively correlated with CRP. However, only use of ESA showed a significant negative correlation with CRP that was independent of other clinical factors and CKD medications on multiple regression analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>ESA may strongly reduce uremic inflammation in addition to improving anemia. To confirm this potential effect, a large-scale longitudinal study would be required.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1476-9255-9-17","type":"journal-article","created":{"date-parts":[[2012,5,14]],"date-time":"2012-05-14T12:16:26Z","timestamp":1336997786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effect of erythropoietin-stimulating agent on uremic inflammation"],"prefix":"10.1186","volume":"9","author":[{"given":"Yuri","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Joki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Hase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Shinoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daijo","family":"Inaguma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Koiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Yamaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Shigematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,14]]},"reference":[{"key":"243_CR1","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/eurheartj\/ehp507","volume":"31","author":"C Ronco","year":"2010","unstructured":"Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House AA, Katz N, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P: Cardio-renal syndromes: Report from the consensus conference of the acute dialysis quality initiative. Eur Hear J. 2010, 31: 703-711. 10.1093\/eurheartj\/ehp507.","journal-title":"Eur Hear J"},{"key":"243_CR2","doi-asserted-by":"crossref","unstructured":"K\/doqi clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005, 45: S1-153.","DOI":"10.1053\/j.ajkd.2005.01.019"},{"key":"243_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1744-9987.2008.00634.x","volume":"12","author":"S Nakai","year":"2008","unstructured":"Nakai S, Masakane I, Akiba T, Shigematsu T, Yamagata K, Watanabe Y, Iseki K, Itami N, Shinoda T, Morozumi K, Shoji T, Marubayashi S, Morita O, Kimata N, Shoji T, Suzuki K, Tsuchida K, Nakamoto H, Hamano T, Yamashita A, Wakai K, Wada A, Tsubakihara Y: Overview of regular dialysis treatment in japan as of 31 december 2006. Ther Apher Dial. 2008, 12: 428-456. 10.1111\/j.1744-9987.2008.00634.x.","journal-title":"Ther Apher Dial"},{"key":"243_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/00365590410031715","volume":"38","author":"Q Yao","year":"2004","unstructured":"Yao Q, Pecoits-Filho R, Lindholm B, Stenvinkel P: Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol. 2004, 38: 405-416. 10.1080\/00365590410031715.","journal-title":"Scand J Urol Nephrol"},{"key":"243_CR5","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1093\/ndt\/gfl037","volume":"21","author":"N Joki","year":"2006","unstructured":"Joki N, Hase H, Tanaka Y, Takahashi Y, Saijyo T, Ishikawa H, Inishi Y, Imamura Y, Hara H, Tsunoda T, Nakamura M: Relationship between serum albumin level before initiating haemodialysis and angiographic severity of coronary atherosclerosis in end-stage renal disease patients. Nephrol Dial Transplant. 2006, 21: 1633-1639. 10.1093\/ndt\/gfl037.","journal-title":"Nephrol Dial Transplant"},{"key":"243_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1527-3466.2006.00033.x","volume":"24","author":"K Prasad","year":"2006","unstructured":"Prasad K: C-reactive protein (crp)-lowering agents. Cardiovasc Drug Rev. 2006, 24: 33-50. 10.1111\/j.1527-3466.2006.00033.x.","journal-title":"Cardiovasc Drug Rev"},{"key":"243_CR7","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S0735-1097(03)00846-5","volume":"42","author":"KK Koh","year":"2003","unstructured":"Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, Shin MS, Ahn TH, Choi IS, Shin EK: Pleiotropic effects of angiotensin ii receptor blocker in hypertensive patients. J Am Coll Cardiol. 2003, 42: 905-910. 10.1016\/S0735-1097(03)00846-5.","journal-title":"J Am Coll Cardiol"},{"key":"243_CR8","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1359\/jbmr.2001.16.11.2057","volume":"16","author":"C Mathieu","year":"2001","unstructured":"Mathieu C, Van Etten E, Gysemans C, Decallonne B, Kato S, Laureys J, Depovere J, Valckx D, Verstuyf A, Bouillon R: In vitro and in vivo analysis of the immune system of vitamin d receptor knockout mice. J Bone Miner Res. 2001, 16: 2057-2065. 10.1359\/jbmr.2001.16.11.2057.","journal-title":"J Bone Miner Res"},{"key":"243_CR9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S0006-8993(02)03239-0","volume":"952","author":"D Agnello","year":"2002","unstructured":"Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines ML, Ghezzi P: Erythropoietin exerts an anti-inflammatory effect on the cns in a model of experimental autoimmune encephalomyelitis. Brain Res. 2002, 952: 128-134. 10.1016\/S0006-8993(02)03239-0.","journal-title":"Brain Res"},{"key":"243_CR10","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.2215\/CJN.00710111","volume":"6","author":"J Bazeley","year":"2011","unstructured":"Bazeley J, Bieber B, Li Y, Morgenstern H, de Sequera P, Combe C, Yamamoto H, Gallagher M, Port FK, Robinson BM: C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients. Clin J Am Soc Nephrol. 2011, 6: 2452-2461. 10.2215\/CJN.00710111.","journal-title":"Clin J Am Soc Nephrol"},{"key":"243_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1053\/j.jrn.2006.10.007","volume":"17","author":"K Taki","year":"2007","unstructured":"Taki K, Niwa T: Indoxyl sulfate-lowering capacity of oral sorbents affects the prognosis of kidney function and oxidative stress in chronic kidney disease. J Ren Nutr. 2007, 17: 48-52. 10.1053\/j.jrn.2006.10.007.","journal-title":"J Ren Nutr"},{"key":"243_CR12","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s11095-007-9248-x","volume":"24","author":"K Shimoishi","year":"2007","unstructured":"Shimoishi K, Anraku M, Kitamura K, Tasaki Y, Taguchi K, Hashimoto M, Fukunaga E, Maruyama T, Otagiri M: An oral adsorbent, ast-120 protects against the progression of oxidative stress by reducing the accumulation of indoxyl sulfate in the systemic circulation in renal failure. Pharm Res. 2007, 24: 1283-1289. 10.1007\/s11095-007-9248-x.","journal-title":"Pharm Res"},{"key":"243_CR13","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/j.jacc.2003.12.051","volume":"43","author":"K Yasunari","year":"2004","unstructured":"Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A: Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol. 2004, 43: 2116-2123. 10.1016\/j.jacc.2003.12.051.","journal-title":"J Am Coll Cardiol"},{"key":"243_CR14","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.clinthera.2005.05.006","volume":"27","author":"LM Ruilope","year":"2005","unstructured":"Ruilope LM, Malacco E, Khder Y, Kandra A, Bonner G, Heintz D: Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: The vast study. Clin Ther. 2005, 27: 578-587. 10.1016\/j.clinthera.2005.05.006.","journal-title":"Clin Ther"},{"key":"243_CR15","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jacc.2004.03.065","volume":"44","author":"B Schieffer","year":"2004","unstructured":"Schieffer B, Bunte C, Witte J, Hoeper K, Boger RH, Schwedhelm E, Drexler H: Comparative effects of at1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol. 2004, 44: 362-368. 10.1016\/j.jacc.2004.03.065.","journal-title":"J Am Coll Cardiol"},{"key":"243_CR16","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1161\/01.CIR.0000140265.21608.8E","volume":"110","author":"D Fliser","year":"2004","unstructured":"Fliser D, Buchholz K, Haller H: Antiinflammatory effects of angiotensin ii subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004, 110: 1103-1107. 10.1161\/01.CIR.0000140265.21608.8E.","journal-title":"Circulation"},{"key":"243_CR17","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1097\/01.TP.0000155305.49439.4C","volume":"79","author":"C Li","year":"2005","unstructured":"Li C, Sun BK, Lim SW, Song JC, Kang SW, Kim YS, Kang DH, Cha JH, Kim J, Yang CW: Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporine-induced nephropathy. Transplantation. 2005, 79: 1522-1529. 10.1097\/01.TP.0000155305.49439.4C.","journal-title":"Transplantation"},{"key":"243_CR18","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.amjcard.2005.01.092","volume":"95","author":"S Koulouris","year":"2005","unstructured":"Koulouris S, Symeonides P, Triantafyllou K, Ioannidis G, Karabinos I, Katostaras T, El-Ali M, Theodoridis T, Vratsista E, Thalassinos N, Kokkinou V, Nanas I, Stamatelopoulos S, Toutouzas P: Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity c-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus. Am J Cardiol. 2005, 95: 1386-1388. 10.1016\/j.amjcard.2005.01.092.","journal-title":"Am J Cardiol"},{"key":"243_CR19","first-page":"211","volume":"15","author":"JP Tsikouris","year":"2004","unstructured":"Tsikouris JP, Suarez JA, Simoni JS, Ziska M, Meyerrose GE: Exploring the effects of ace inhibitor tissue penetration on vascular inflammation following acute myocardial infarction. Coronary Artery Dis. 2004, 15: 211-217.","journal-title":"Coronary Artery Dis"},{"key":"243_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/sj.jhh.1001812","volume":"19","author":"MT Schram","year":"2005","unstructured":"Schram MT, van Ittersum FJ, Spoelstra-de Man A, van Dijk RA, Schalkwijk CG, Ijzerman RG, Twisk JW, Stehouwer CD: Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type ii diabetic individuals: Effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. J Hum Hypertens. 2005, 19: 429-437. 10.1038\/sj.jhh.1001812.","journal-title":"J Hum Hypertens"},{"key":"243_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.amjcard.2004.08.064","volume":"95","author":"MJ Hung","year":"2005","unstructured":"Hung MJ, Cherng WJ, Cheng CW, Yang NI: Effect of antispastic agents (calcium antagonists and\/or isosorbide dinitrate) on high-sensitivity c-reactive protein in patients with coronary vasospastic angina pectoris and no hemodynamically significant coronary artery disease. Am J Cardiol. 2005, 95: 84-87. 10.1016\/j.amjcard.2004.08.064.","journal-title":"Am J Cardiol"},{"key":"243_CR22","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1291\/hypres.31.1147","volume":"31","author":"S Ogawa","year":"2008","unstructured":"Ogawa S, Mori T, Nako K, Ito S: Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. Hypertens Res. 2008, 31: 1147-1155. 10.1291\/hypres.31.1147.","journal-title":"Hypertens Res"},{"key":"243_CR23","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A: Revised equations for estimated gfr from serum creatinine in japan. Am J Kidney Dis. 2009, 53: 982-992. 10.1053\/j.ajkd.2008.12.034.","journal-title":"Am J Kidney Dis"},{"key":"243_CR24","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1744-9987.2010.00893.x","volume":"14","author":"S Nakai","year":"2010","unstructured":"Nakai S, Suzuki K, Masakane I, Wada A, Itami N, Ogata S, Kimata N, Shigematsu T, Shinoda T, Syouji T, Taniguchi M, Tsuchida K, Nakamoto H, Nishi S, Nishi H, Hashimoto S, Hasegawa T, Hanafusa N, Hamano T, Fujii N, Marubayashi S, Morita O, Yamagata K, Wakai K, Watanabe Y, Iseki K, Tsubakihara Y: Overview of regular dialysis treatment in japan (as of 31 december 2008). Ther Apher Dial. 2010, 14: 505-540. 10.1111\/j.1744-9987.2010.00893.x.","journal-title":"Ther Apher Dial"},{"key":"243_CR25","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1046\/j.1523-1755.1999.00422.x","volume":"55","author":"P Stenvinkel","year":"1999","unstructured":"Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999, 55: 1899-1911. 10.1046\/j.1523-1755.1999.00422.x.","journal-title":"Kidney Int"},{"key":"243_CR26","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00467-008-1046-0","volume":"24","author":"DM Silverstein","year":"2009","unstructured":"Silverstein DM: Inflammation in chronic kidney disease: Role in the progression of renal and cardiovascular disease. Pediatr Nephrol. 2009, 24: 1445-1452. 10.1007\/s00467-008-1046-0.","journal-title":"Pediatr Nephrol"},{"issue":"Suppl 1","key":"243_CR27","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1681\/ASN.2004110972","volume":"16","author":"G Tripepi","year":"2005","unstructured":"Tripepi G, Mallamaci F, Zoccali C: Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with esrd: Searching for the best risk marker by multivariate modeling. J Am Soc Nephrol. 2005, 16 (Suppl 1): S83-S88.","journal-title":"J Am Soc Nephrol"},{"key":"243_CR28","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/sj.ki.5001726","volume":"70","author":"H Hase","year":"2006","unstructured":"Hase H, Tsunoda T, Tanaka Y, Takahashi Y, Imamura Y, Ishikawa H, Inishi Y, Joki N: Risk factors for de novo acute cardiac events in patients initiating hemodialysis with no previous cardiac symptom. Kidney Int. 2006, 70: 1142-1148. 10.1038\/sj.ki.5001726.","journal-title":"Kidney Int"},{"key":"243_CR29","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1056\/NEJM199902113400607","volume":"340","author":"C Gabay","year":"1999","unstructured":"Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999, 340: 448-454. 10.1056\/NEJM199902113400607.","journal-title":"N Engl J Med"},{"key":"243_CR30","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1291\/hypres.26.691","volume":"26","author":"Y Dohi","year":"2003","unstructured":"Dohi Y, Ohashi M, Sugiyama M, Takase H, Sato K, Ueda R: Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens Res. 2003, 26: 691-697. 10.1291\/hypres.26.691.","journal-title":"Hypertens Res"},{"key":"243_CR31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.atherosclerosis.2007.09.039","volume":"199","author":"K Kourea","year":"2008","unstructured":"Kourea K, Parissis JT, Farmakis D, Panou F, Paraskevaidis I, Venetsanou K, Filippatos G, Kremastinos DT: Effects of darbepoetin-alpha on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble fas\/fas ligand system in anemic patients with chronic heart failure. Atherosclerosis. 2008, 199: 215-221. 10.1016\/j.atherosclerosis.2007.09.039.","journal-title":"Atherosclerosis"},{"key":"243_CR32","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","volume":"360","author":"BC Fellstrom","year":"2009","unstructured":"Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009, 360: 1395-1407. 10.1056\/NEJMoa0810177.","journal-title":"N Engl J Med"},{"key":"243_CR33","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005, 353: 238-248. 10.1056\/NEJMoa043545.","journal-title":"N Engl J Med"}],"container-title":["Journal of Inflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-9255-9-17.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T19:46:42Z","timestamp":1630525602000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal-inflammation.biomedcentral.com\/articles\/10.1186\/1476-9255-9-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,14]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["243"],"URL":"https:\/\/doi.org\/10.1186\/1476-9255-9-17","relation":{},"ISSN":["1476-9255"],"issn-type":[{"value":"1476-9255","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,14]]},"assertion":[{"value":"14 December 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"17"}}